Literature DB >> 10498253

Costimulation of transduced T lymphocytes via T cell receptor-CD3 complex and CD28 leads to increased transcription of integrated retrovirus.

K E Pollok1, J C van der Loo, R J Cooper, L Kennedy, D A Williams.   

Abstract

Primary human T lymphocytes were transduced at high efficiency with the Moloney murine leukemia virus (Mo-MuLV) vector, LNC-mB7-1, in which an internal cytomegalovirus (CMV) promoter drives expression of the murine B7-1 cDNA. Compared with transduced T cells expanded in IL-2 or reactivated with soluble antibodies to CD3 or CD28, transgene expression was significantly increased after activation on immobilized anti-CD3 antibodies (CD3i) or by simultaneous activation on immobilized anti-CD3 and anti-CD28 antibodies (CD3i/CD28i). A similar pattern of transgene expression was observed in T cells transduced with Mo-MuLV LNC-EGFP. Proviral copy number was maintained in LNC-mB7-1-transduced T cells expanded in IL-2 or reactivated on CD3i/CD28i. Substantial increases in LNC-mB7-1 steady state mRNA in reactivated T lymphocytes, compared with those maintained in IL-2, correlated with increased transcription of the LNC-mB7-1 proviral DNA. Furthermore, T cells transduced with the Mo-MuLV ZIPPGK-mADA, in which the mADA cDNA is driven by an internal human phosphoglycerate kinase (PGK) promoter, showed increases in steady state ZIPPGK-mADA RNA on reactivation. High levels of transgene expression were evident irrespective of cell cycle position in both CD4+ and CD8+ lymphocytes. After reactivation, increases in LNC-mB7-1 mRNA were observed in the presence of the protein synthesis inhibitor cycloheximide, indicating that proteins involved in upregulating transgene expression preexisted in transduced lymphocytes. Induction of transgene expression on CD3i/CD28i showed a dose-dependent decrease in transgene expression when incubated with selective protein kinase inhibitors. These data provide new insights into the mechanisms governing transgene expression driven by Mo-MuLV constructs containing internal promoters in transduced primary T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10498253     DOI: 10.1089/10430349950017202

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  9 in total

1.  Efficient Transduction of Human and Rhesus Macaque Primary T Cells by a Modified Human Immunodeficiency Virus Type 1-Based Lentiviral Vector.

Authors:  Huan He; Jing Xue; Weiming Wang; Lihong Liu; Chaobaihui Ye; Zhe Cong; Jason T Kimata; Chuan Qin; Paul Zhou
Journal:  Hum Gene Ther       Date:  2016-12-29       Impact factor: 5.695

2.  A Good Manufacturing Practice procedure to engineer donor virus-specific T cells into potent anti-leukemic effector cells.

Authors:  Marleen M van Loenen; Renate de Boer; Ellis van Liempt; Pauline Meij; Inge Jedema; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Haematologica       Date:  2013-12-13       Impact factor: 9.941

3.  Rac2, a hematopoiesis-specific Rho GTPase, specifically regulates mast cell protease gene expression in bone marrow-derived mast cells.

Authors:  Yi Gu; Michael C Byrne; Nivanka C Paranavitana; Bruce Aronow; Jamie E Siefring; Maria D'Souza; Heidi F Horton; Lawrence A Quilliam; David A Williams
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

4.  Retroviral-mediated gene transfer in primary murine and human T-lymphocytes.

Authors:  I Rivière; H F Gallardo; A B Hagani; M Sadelain
Journal:  Mol Biotechnol       Date:  2000-06       Impact factor: 2.695

5.  Retrovirally transduced murine T lymphocytes expressing FasL mediate effective killing of prostate cancer cells.

Authors:  J C Symes; C Siatskas; D H Fowler; J A Medin
Journal:  Cancer Gene Ther       Date:  2008-12-19       Impact factor: 5.987

6.  Regulatory T-cell expansion and function do not account for the impaired alloreactivity of ex vivo-expanded T cells.

Authors:  Nicolas Montcuquet; Patricia Mercier-Letondal; Sylvain Perruche; Anne Duperrier; Mélanie Couturier; Abdelghani Bouchekioua; Mark Bonyhadi; Christophe Ferrand; Pierre Tiberghien; Eric Robinet
Journal:  Immunology       Date:  2008-04-26       Impact factor: 7.397

7.  Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation.

Authors:  William R Burns; Zhili Zheng; Steven A Rosenberg; Richard A Morgan
Journal:  Blood       Date:  2009-07-09       Impact factor: 22.113

8.  Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent.

Authors:  Ke Liu; Steven A Rosenberg
Journal:  J Immunother       Date:  2003 May-Jun       Impact factor: 4.456

9.  Inducible apoptosis as a safety switch for adoptive cell therapy.

Authors:  Antonio Di Stasi; Siok-Keen Tey; Gianpietro Dotti; Yuriko Fujita; Alana Kennedy-Nasser; Caridad Martinez; Karin Straathof; Enli Liu; April G Durett; Bambi Grilley; Hao Liu; Conrad R Cruz; Barbara Savoldo; Adrian P Gee; John Schindler; Robert A Krance; Helen E Heslop; David M Spencer; Cliona M Rooney; Malcolm K Brenner
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.